Note: Descriptions are shown in the official language in which they were submitted.
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
FATTY ALCOHOLS AND FATTY ACID ESTERS USEFUL FOR
TREATMENT OF INFLAMMATION
FIELD OF THE INVENTION
The present invention relates to anti-inflammatory agents and, more
particularly, to fatty alcohols, esters thereof with C1 - C6 alkanoic acids or
esters of
fatty acids with alkanediols or glycerol which are useful in the treatment of
immunologically-mediated inflammation.
Abbreviations: AA: adjuvant arthritis: CFA: complete Freund's adjuvant; EAE:
experimental autoimmune encephalomyelitis; GPSCH: guinea pig spinal cord
homogenate; IFA: incomplete Freund's adjuvant; OA: oleyl alcohol; PBS:
phosphate-buffered saline; SC: subcutaneously.
BACKGROUND OF THE INVENTION
Inflammation is commonly divided into three phases: acute inflammation, the
immune response and chronic inflammation. Acute inflammation is the initial
response to tissue injury and is mediated by the release of histamine,
serotonin,
bradykinin, prostaglandins and leukotrienes. The immune response, usually
preceded
by the acute inflammation phase, occurs when immunologically competent cells
are
activated in response to foreign organisms or antigenic substances liberated
during
the acute or chronic inflammatory response. The outcome of the immune response
for the host may be beneficial, as when it causes invading organisms to be
phagocytosed or neutralized. However, the outcome may be deleterious if it
leads to
chronic inflammation without resolution of the underlying injurious process as
it
occurs in rheumatoid arthritis.
1
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
The treatment of patients with inflammation envisages the relief of pain,
which is the presenting symptom and the major continuing complaint of the
patient,
as well as the slowing or arrest of the tissue-damaging process.
Anti-inflammatory agents are usually classified as steroidal or
glucocorticoids
and nonsteroidal anti-inflammatory agents (NSAIDs). The glucocorticoids are
powerful anti-inflammatory agents but the high toxicity associated with
chronic
corticosteroid therapy inhibits their use except in certain acute inflammatory
conditions. Therefore, the nonsteroidal anti-inflammatory drugs have assumed a
maj or role in the treatment of chronic conditions such as rheumatoid
arthritis.
Among the nonsteroidal anti-inflammatory agents are included derivatives of
aminoarylcarboxylic acids, arylacetic acids, arylbutyric acids, arylcarboxylic
acids,
arylpropionic acids, pyrazole, pyrazolone, salicylic acid and some other
derivatives
of different chemical structure, including specific anti-arthritic/anti-
rheumatic
agents.
Some fatty alcohols and esters of fatty acids have been described as solvents
or emulsifiers for use in pharmaceutical compositions. For example, cetyl
alcohol
may be used in pharmaceutical compositions as emulsifying and stiffening agent
(The Merck Index, pp. 347-8, # 2037), oleyl alcohol may be used as a carrier
for
medicaments (The Merck Index, p. 1222, # 6900), and alkyl esters of oleic acid
may
be used as solvents for medicaments (The Merck Index, p. 6899, # 6898).
A mixture of higher aliphatic primary alcohols, primarily isolated from
beeswax, was described as having moderate anti-inflammatory activity. The
composition of such a mixture was not disclosed (Rodriguez et al., 1998).
Feeding laboratory animals with fish oil rich in the long-chain n-3
polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (20:5n-3) and
docosahexaenoic acid (22:6n-3), was described to reduce acute and chronic
inflammatory responses, to improve survival to endotoxin and in models of
autoimmunity and to prolong the survival of grafted organs, and it was
therefore
suggested that fish oil supplementation may be clinically useful in acute and
chronic
inflammatory conditions and following transplantation (Calder, 1998). A
2
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic
acid
for treatment of schizophrenia is described in WO 98/16216 and US 6,331,568.
Modified polyunsaturated fatty acids and derivatives thereof have been
proposed for pharmaceutical uses. WO 99/27924 and US 6,280,755 describe anti
s inflammatory fatty acids uninterrupted by a methylene group for use in
topical
pharmaceutical and cosmetic compositions. WO 97/38688 and US 6,262,119
describe polyunsaturated fatty acids having 1 or 2 substitutions selected from
oxa
and thia in position beta or gamma to the acyl group, for treating or
ameliorating
symptoms of T-cell mediated disease. WO 99/58122 and US 6,365,628 describe
saturated fatty acids in which one or more methylene groups are substituted by
O, S,
SO, SOZ, or Se and alkyl esters thereof, for treatment or prevention of
diabetes. US
5,019,383 describes synthetic vaccines comprising a peptide residue coupled to
one
or more alkyl or alkenyl groups of at least 12 carbon atoms or other
lipophilic
substance, wherein said alkyl or alkenyl group may be a fatty acid residue
coupled to
one or more functional groups of a polyfunctional group which is bound to the
N
terminal amino group and/or C-terminal carboxy group of the peptide residue.
There is no description in the literature that isolated fatty alcohols or
esters
thereof with alkanoic acids may be used themselves as medicaments, and
specifically
not that they may be involved in immunomodulation of inflammation.
SUMMARY OF THE INVENTION
It has now been surprisingly found, in accordance with the present invention,
that certain long-chain fatty alcohols, esters thereof with C1 - C6 alkanoic
acids, or
certain esters of long-chain fatty acids with alkanediols or glycerol can
suppress
inflammation in experimental adjuvant arthritis (AA) and experimental
autoimlnune
encephalomyelitis (EAE) models in rats and can prevent graft rej ection in
mice.
The present invention thus relates to pharmaceutical compositions for the
treatment of inflammation, particularly immunologically-mediated inflammation,
comprising as active ingredient an immunomodulator selected from: (a) a
saturated
or cis-unsaturated Cio - C2o fatty alcohol or an ester thereof with a C1 - C6
alkanoic
3
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
acid; (b) a monoester of a C2 - C8 alkanediol or of glycerol with a saturated
or cis-
unsaturated Clo - Cao fatty acid; and (c) a diester of glycerol with a
saturated or cis-
unsaturated Clo- Cao fatty acid.
In another embodiment, the invention relates to the use of an
immunomodulator selected from: (a) a saturated or cis-unsaturated Clo - C2o
fatty
alcohol or an ester thereof with a Cl - C6 alkanoic acid; (b) a monoester of a
CZ - C8
alkanediol or of glycerol with a saturated or cis-unsaturated Clo - Czo fatty
acid; and
(c) a diester of glycerol with a saturated or cis-unsaturated Clo - Cao fatty
acid, for
the preparation of a pharmaceutical composition for the treatment of
inflammation,
in particular immunologically-mediated inflammation.
In still another embodiment, the invention relates to a method for the
treatment of inflammatory disorders, in particular immunologically-mediated
inflammation, which comprises administering to an individual in need thereof
an
effective amount of an agent selected from an immunomodulator selected from:
(a) a
saturated or cis-unsaturated Clo - Cao fatty alcohol or an ester thereof with
a Ci - C6
allcanoic acid; (b) a monoester of a CZ - Cg alkanediol or of glycerol with a
saturated
or cis-unsaturated Clo - Czo fatty acid; and (c) a diester of glycerol with a
saturated
or cis-unsaturated Clo - Cao fatty acid.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the dose response effect of oleyl alcohol (OA) on adjuvant
arthritis (AA). Different doses of OA were administered subcutaneously to rats
once
14 days before induction of AA.
Fig. 2 is a graph showing the disease profile of Lewis rats with experimental
autoimmune encephalomyelitis (EAE) and treated with oleyl alcohol. Oleyl
alcohol
was administered to the rats 14 days before induction of EAE. Control group
was
treated with incomplete Freund's adjuvant (IFA).
Fig. 3 is a graph showing the disease profile of Lewis rats with EAE and
treated with IFA. IFA was administered to the rats 14 days before induction of
EAE.
Control group was not treated.
4
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides immunomodulators selected from: (a) a
saturated or cis-unsaturated Clo - Cao fatty alcohol or an ester thereof with
a C1 - C6
alkanoic acid; (b) a monoester of a Ca - Cg alkanediol or of glycerol with a
saturated
or cis-unsaturated Clo - C2o fatty acid; and (c) a diester of glycerol with a
saturated
or cis-unsaturated Clo - Cao fatty acid.
According to one preferred embodiment of the invention, the pharmaceutical
composition comprises a long-chain saturated or unsaturated Clo-Cao,
preferably C16-
C2o, most preferably a C18, fatty alcohol.
Examples of Cio-Cao saturated fatty alcohols that can be used according to the
invention include, but are not limited to, decyl alcohol, lauryl alcohol,
myristyl
alcohol, stearyl alcohol and preferably cetyl alcohol (also known as palmityl
alcohol).
.- The unsaturated fatty alcohol according to the invention has preferably one
or
more double bonds in the cis form and 16-18 carbon atoms and may be, without
being limited to, oleyl alcohol (cis-9-octadecenol), linoleyl alcohol (cis-
9,12-
octadecadienol), y-linolenyl alcohol (cis-6,9,12-octadecatrienol) and
linolenyl
alcohol (cis-9,12,15-octadecatrienol). In preferred embodiments, the fatty
alcohol
used in the compositions of the invention is cetyl, linolenyl or, most
preferably, oleyl
alcohol.
In another embodiment, the pharmaceutical composition of the invention
comprises an ester of a fatty alcohol as defined above with a C1 - C6 alkanoic
acid
such as acetic acid, propionic acid, butyric acid, valeric acid and caproic
acid.
In a further embodiment, the pharmaceutical composition of the invention
comprises an ester of a saturated or cis-unsaturated Clo-Cao fatty acid with
an alcohol
selected from a C2-C8 alkanediol or glycerol, said ester being a monoester
with said
C2-C8 alkanediol or glycerol or a diester with glycerol.
The Clo-Czo fatty acid is preferably a C16-C2o, most preferably a C18 fatty
acid.
In one embodiment, the Clo-C2o fariy acid is saturated such as, but without
being
5
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
limited to, capric acid, lauric acid, myristic acid, palmitic acid, stearic
acid and
arachidic acid. In another embodiment, the Clo-Cao fatty acid is a cis-
unsaturated
fatty acid such as, but without being limited to, palmitoleic acid (cis-9-
hexadecenoic
acid), oleic acid (cis-9-octadecenoic acid), cis-vaccenic acid (cis-11-
octadecenoic
acid), linoleic acid (cis-9,12-octadecadienoic acid), y-linolenic acid (cis-
6,9,12-
octadecatrienoic acid), linolenic acid (cis-9,12,15-octadecatrienoic acid) and
arachidonic acid (cis-5, 8,11,14-eicosatetraenoic acid).
According to the invention, the alkanediol has 2 to 8, preferably 2 to 4, and
more preferably, 2 carbon atoms, and is selected from, but not being limited
to, 1,3
propanediol, 1,4-butanediol and, preferably, 1,2-ethylene glycol. An example
of
such an ester is 1,2-ethylene glycol monooleate.
According to another embodiment of the invention, the active ingredient of
the pharmaceutical composition is a mono- or diester of glycerol with the long-
chain
fatty acid. In one preferred embodiment, the monoglyceride is glycerol
monooleate.
The diglycerides contain one free hydroxyl group and the other two hydroxyl
groups
may be both esterified with 2 molecules of the long-chain fatty acid, e.g.
glycerol
dioleate, or one of the hydroxyl groups is esterified with one molecule of the
long-
chain fatty acid and a second hydroxyl group is esterified with a C1 - C6
alkanoic
acid such as acetic acid, propionic acid, butyric acid, valeric acid and
caproic acid.
The immune system, in both its innate and adaptive arms, is involved in
regulating inflammation of every type, and inflammation is a key factor in
processes
such as wound healing, connective tissue re-modeling, angiogenesis, organ
regeneration, neuroprotection, as well as in the adaptive immune responses
seen in
autoimmunity, allergies, graft rejection, and infection (see Cohen, 2000;
Schwartz
and Cohen, 2000). Therefore, anti-inflammatory agents that modulate the
inflammatory response such as those described here will be useful in a variety
of
conditions.
Inflammatory disorders that can be treated with the immunomodulators of the
present invention include, but are not limited to, immunologically-mediated
chronic
or acute inflammatory disorders selected from an autoimmune disease, severe
6
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
allergies, asthma, graft rejection or for the treatment of chronic
degenerative diseases
such as Alzheimer's disease, and in neuroprotection, organ regeneration,
chronic
ulcers of the skin, and schizophrenia.
Examples of autoimmune diseases that can be treated according to the
invention are multiple sclerosis or a human arthritic condition, e.g.
rheumatoid
arthritis, reactive arthritis with Reiter's syndrome, ankylosing spondylitis
and other
inflammations of the j oints mediated by the immune system. Other autoimmune
diseases are contemplated and are presented in the following list in the
context of the
organ or tissue involved. Thus, according to the invention, the
immunologically-
mediated inflammatory disorder may be myasthenia gravis, Guillain-Barre
syndrome, and other inflammatory diseases of the nervous system; psoriasis,
pemphigus vulgaris and other diseases of the skin; systemic lupus
erythematosus,
glomerulonephritis and other diseases affecting the kidneys; atherosclerosis
and
other inflammations of the blood vessels; autoimmune hepatitis, inflammatory
bowel diseases, e.g. Crohn's disease, pancreatitis, and other conditions of
the
gastrointestinal system; type 1 diabetes mellitus (insulin-dependent diabetes
mellitus
or IDDM), autoilnlnune thyroiditis (Hashimoto's thyroiditis), and other
diseases of
the endocrine system.
One of the models used to test the anti-inflammatory activity of the agents
according to the invention is adjuvant arthritis (AA), an experimental disease
of the
joints inducible in some strains of rats by immunizing with Mycobacterium
tuberculosis in complete Freund's adjuvant (CFA). These animals develop an
arthritis whose features are similar to those of rheumatoid arthritis in
humans and
thus serve as animal models of human arthritic conditions such as rheumatoid
arthritis, reactive arthritis in Reiter's syndrome, ankylosing spondylitis and
other
inflammations of the joints which appear to be mediated by the immune system
(Pearson, 1964). Adjuvant arthritis also serves as a model of immune-mediated
inflammation in general including cell-mediated autoimmune reactions, graft
rejection and allergic reaction. For example, treatments which can suppress
rheumatoid arthritis include immunosuppressive agents such as corticosteroids,
7
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
cyclosporin A (Jaffee et al., 1989; Pollock et al., 1989), azathioprine, and
other
immunosuppressive agents which are broadly used in the treatment of autoimmune
diseases. Therefore, suppression of adjuvant arthritis by a therapeutic agent
indicates
that the agent is potentially useful as a broad anti-inflammatory agent.
The pharmaceutical composition provided by the present invention may be in
solid, semisolid or liquid form and may further include pharmaceutically
acceptable
fillers, carriers or diluents, and other inert ingredients and excipients. The
composition can be administered by any suitable route such as, but not limited
to,
oral, topical, or parenteral e.g. by injection through subcutaneous,
intravenous,
intramuscular, or any other suitable route. Since many of the compounds are
oily,
they are preferably administered parenterally, more preferably subcutaneously.
If
given continuously, the compounds of the present invention are each typically
administered by 1-4 injections per day or by continuous subcutaneous
infusions, for
example, using a mini-pump. The dosage will depend of the state of the patient
and
severity of the disease and will be determined as deemed appropriate by the
practitioner.
For parenteral administration, the compounds may be formulated by mixing
each at the desired degree of purity, in a unit dosage injectable form
(solution,
suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e.,
one that is
non-toxic to recipients at the dosages and concentrations employed and is
compatible with other ingredients of the formulation. Generally, the
formulations
are prepared by contacting the compounds of the present invention each
uniformly
and intimately with liquid carriers or finely divided solid carriers or both.
Then, if
necessary, the product is shaped into the desired formulation. Preferably the
carrier
is a parenteral carrier, more preferably a solution that is isotonic with the
blood of
the recipient. Examples of such carrier vehicles include water, saline,
Ringer's
solution, and dextrose solution. Non-aqueous vehicles such as fixed oils can
be also
useful, as well as liposomes. These preparations can be made by conventional
methods known to those skilled in the art, for example as described in
"Remington's
8
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
Pharmaceutical Science", A.R. Gennaro, ed., 17th edition, 1985, Mack
Publishing
Company, Easton, PA, USA.
The invention will now be illustrated by the following non-limiting examples.
EXAMPLES
Example 1. Anti-inflammatory effect of oleyl alcohol and other a~ents-
protection against adjuvant arthritis (AA)
AA was induced by immunizing inbred 8-10-week old Lewis rats (Harlan-
Olac Limited, Blackthorn, Oxon, UI~), at the base of the tail with 1 mg/0.1 ml
of
killed Mycobacterium tuberculosis (Sigma) in IFA (Sigma) as described
(Pearson,
1956). Arthritis of the limbs was noted to develop 12-14 days later and was
scored
on a scale of 0-16 summing the severity of the inflammation of each of the 4
limbs
on a scale of 0-4, as described (Holoshitz et al., 1983). The peak of the
arthritis
usually was observed around day 26 after immunization.
Control rats were untreated or treated by injections of saline. A positive
control of immunosuppression was obtained by including a group of rats treated
with
the corticosteroid agent dexamethasone (200 ~,g) administered
intraperitoneally
every other day beginning on day 12 after induction.
The immunomodulator of the invention (100 ~,1 oleyl alcohol, glycerol mono-
oleate, linolenyl alcohol or cetyl alcohol) was administered subcutaneously
(SC)
once 14 days before induction of AA or on day 12 after induction of AA. The
percent inhibition of inflammation measured on the day of maximal inflammation
was computed as follows:
mean maximal score of test groin x 100%
mean maximal score of control group
All four compounds were found to be effective, producing more than 60%
inhibition of inflammation whereas oleic acid had no effect. The results are
summarized in Table 1.
9
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
Two further experiments showed that 500 ~l of oleyl alcohol (100 ~,1
corresponds to about 90 mg oleyl alcohol) suppressed the inflammation by 96%
and
91 %.
Table 1. Effects of various agents on the inflammation of adjuvant arthritis
Compound Tested % Inhibition (100
~ul~
Glycerol mono-oleate 98%
Oleyl alcohol 78%
Linolenyl alcohol 75%
Cetyl alcohol 66%
Example 2. Protection against AA by different doses of oleyl alcohol
To study the dose response effect of oleyl alcohol in AA, oleyl alcohol was
administered subcutaneously in doses of 10, 50, 100 or 500 mg to Lewis rats
once 14
days before induction of AA, as described in Example 1 above.
Fig. 1 shows the dose response effect of oleyl alcohol. It can be seen that
increasing doses of oleyl alcohol suppressed the arthritis. On the day of peak
disease,
day 26, the inflammation was suppressed by 14% (10 ~l), 61% (50 ~1), 78% (100
~,1)
and 90% (500 ~.1).
Example 3. Anti-inflammatory effect of oleyl alcohol and other
immunomodulators and ~~rotection against EAE in DA rats
Experimental autoimmune encephalomyelitis (EAE) is an experimental
autoimmune disease inducible in some strains of rats by immunization with
myelin
basic protein (MBP) or proteolipid protein (PLP) in complete Freund's adjuvant
(CFA) or with an emulsion of the rat's spinal cord in either CFA or incomplete
Freund's adjuvant (IFA). EAE in DA rats is considered as a model of chronic
EAE.
Within two to three weeks the animals develop cellular infiltration of the
myelin
sheaths of the central nervous system resulting in demyelination and
paralysis. Most
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
of the animals die, but others have milder symptoms, and some animals develop
a
chronic form of the disease that resembles chronic relapsing and remitting
multiple
sclerosis (MS) in humans. Therefore, these animals with EAE serve as a model
for
the human MS autoimmune disease. EAE develops in the animal about 12 days
after
immunization and is characterized by paralysis of various degrees due to
inflammation of the central nervous system. In some strains, like the Lewis
rat, the
paralysis can last up to 6-7 days and the rats usually recover unless they die
during
the peak of their acute paralysis. In other strains of rats like the DA rat,
the paralysis
can be chronic and remitting.
For the induction and clinical assessment of EAE, spinal cord obtained from
DA rats is frozen, thawed and minced thoroughly with a spatula before
immunization. Rats are immunized by one subcutaneous injection (just under the
skin) into the dorsal base of the tail with 200 ~,1 emulsion prepared from 1:1
IFA
(Difco, Detroit, MI, USA) and antigen (volume/weight, i.e. 100 ~,1 IFA/100 mg
of
whole spinal cord) or from 1:1 CFA (IFA was complemented with 4 mg/ml of
Mycobacte~iuyn tuberculosis strain 37RA) and antigen (volume/weight, i.e. 100
~.1
CFA/100 mg of whole spinal cord). The emulsion was prepared by titration with
a
gas-tight glass syringe and a needle, 1.2 mm diameter. Rats are regularly
weighed
and examined for clinical signs of EAE. A four-graded scale was used to assess
clinical severity: 0, no paralysis; 1, tail weakness (hanging); 2, hind limb
paralysis;
3, hind and fore limb paralysis; 4, severe total paralysis (Lorentzen et al.,
1995).
Groups of 5 or 7 DA strain female rats, 8-9 week old, are immunized in the
hind footpads with 0.1 ml per footpad of IFA containing 100 mg of whole,
homogenized DA spinal cord, for a total of 200 mg per rat. On the day of
immunization, the rats are treated by SC injection with oleyl alcohol or other
agent
according to the invention (100 ~,1) or with paraffin oil (control). The rats
are scored
for EAE on a severity scale of 0 - 4 as described above.
11
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
Example 4. Anti-inflammatory effect of olevl alcohol and urotection against
EAE in Lewis rats
EAE induced in Lewis rats is considered as a model of acute inflammation in
the brain (as opposed to the chronic disease in DA rats).
For EAE induction, three lyophilized guinea pig spinal cord homogenate
(GPSCH) emulsions were prepared as follows: (i) 25 mg of lyophilized GPSCH
(GP2) was suspended in 2.5 ml of sterile PBS (Sigma) and incubated for one
hour at
37° C; (ii) 54.1 mg' of Mycobacterium tuberculosis H37Ra (MT, Difco)
was
suspended in 13.5 ml CFA (Sigma) containing lmg/ml MT to obtain 5 mg/ml MT;
(iii) 2.5 ml CFA (5 mg/ml MT) was added into vial with 2.5 ml of PBS
containing
25 mg GPSCH to yield 5 mg/ml GPSCH and 2.5 mg/ml MT. The mixture was
transferred into a glass syringe connected to a second glass syringe through a
Luer
lock bridge. The material was mixed well by transferring from one syringe to
another
for about 10 minutes until the materiall was well emulsified. The emulsion of
GPSCH at a dose of 1 mg/rat and MT at a dose of 0.5 mg/rat in CFA induced EAE
in
rats (based on previous titration).
For the treatment, two groups of eight 9-10 weeks old Lewis rats (Harlan,
Israel), were treated with the test samples (oleyl alcohol or IFA) 14 days
before EAE
induction. The group treated with IFA served as the control group. The test
samples
were injected at a dose of 0.5 ml/kg once, subcutaneously. A third group of 8
rats
was not treated and served as non-treated control.
EAE was induced in rats of all three groups 14 days after injection of the
test
samples by injection with 0.1 ml of the GPSCH emulsion in CFA into each of the
hind leg foot pads (0.2 ml per rat).
The EAE clinical signs were observed and scored from the 9~' day post-EAE
induction until the termination of the experiment according to the following
five
graded scale to assess clinical severity: 0, normal behavior; 1, weight loss;
2, tail
weakness; 3, hind legs hypotonia and weakness; 4, hind legs paralysis; 4,
severe total
paralysis; 5, impaired respiration and/or convulsions and/or full paralysis or
death.
All rats having scores of 1 and above were considered sick.
12
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
The calculation of EAE results was carried out as follows:
(i) Calculation of the incidence of disease
The number of sick animals in each group were summed. The incidence of
disease and the % activity were calculated as follows:
Incidence of disease = No. of sick rats in _~rou~ x 100%
No. of rats in group
activity * = 1 _ (disease incidence in treated -group ) x 100%
disease incidence in control group
* _ (according to incidence)
(ii) Calculation of the mean maximal scope (MMS)
The maximal score of each rat in the group were summed. The mean maximal
score (MMS) and the % activity of the group were calculated as follows:
Maximal score of each rat
Mean Maximal score =
No. of rats in the group
activity * _ ( 1 _ ~S of treated group ) ~ 100
MMS of control group
* _ (% activity according to MMS)
(iii) Caleulatio~ of the group mean scope (GMS)
The mean score of each rat during the observation period were summed
(score 5 was counted forward). The mean score of the group and its % activity
were
calculated as follows:
Mean score =
Group score of each rat
No. of rats in the group
activity * _ (1_GMS of treated group ) x 100
GMS of control group
* _ (% activity according to GMS)
13
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
(iv) Calculation of the mean onset of disease
The time of disease onset (days) for each rat in the group were summed. The
mean onset of disease for the group was calculated. The time of onset of
disease for
those rats that did not develop EAE was considered as 25 days (duration of
study).
(v) Calculation of the mean duration of disease
The disease duration (days) of each rat in each group were summed. The mean
disease duration of the group was calculated. The disease duration of rats
that did not
develop EAE was considered as zero.
The evaluation of the clinical manifestations of EAE, i.e. % incidence of
disease, MMS, GMS, mean duration and onset of EAE disease is summarized in
Table 2. The graphs of the disease profile for each group are presented in
Figs. 2 and
3 for treatment with oleyl alcohol and IFA, respectively.
As shown by the results, no essential difference in incidence of disease
(62.5% to 75% incidence) or mean maximum score (1.75 to 2.38 MMS) was
observed between the IFA-injected groups and non-treated control group. Oleyl
alcohol showed a beneficial effect on all the clinical parameters that were
tested. It
exhibited 77.1% activity according to group mean score (GMS) and 63% activity
according to mean maximum score (MMS) compared to the non-treated control
group. The mean onset of disease was 18.6 days in the oleyl alcohol treated
group
compared to 15.5 days in the non-treated control group. The duration of
disease was
2.0 days in the oleyl alcohol treated group compared to 5.13 days in the non-
treated
control group. The duration of the EAE clinical signs in the tested groups was
between 1 and 7 days, except one rat in the group treated with IFA. IFA had
minor
effect, if any, on the rat EAE. No mortality was observed in the tested
groups, except
one rat in the non-treated control group.
14
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
Table 2: Evaluation EAE clinical results
GroupTest % % MMS % GMS % Mean Disease
No. Sample Incid-Activity Activity ActivityOnset duration
ence Incidence MMS GMS of disease(days)
(Day
No.)
1 OA 50.0%33.3% 0.88 63.0% 0.2277.1% 18.6 2.0
2 IFA 62.5%16.7% 1.75 26.5% 0.5245.8% 17.0 3.75
3 NTC 75.0%N~ 2.38 NA 0.96NA 15.5 5.13
I I I
OA-Oleyl alcohol; NTC-non-treated control; NA- Not applicable
Example 5. Effect of oleyl alcohol on skin allo~raft survival
The immune system represents a strong barrier for successful transplantation
of organs or tissues between non-genetically identical donor and recipient.
Both
CD4+ and CD8+ T cells participate in graft rejection.
Skin graft transplantation is carried out essentially as described before
(Birk
et al., 1999). Thus, mice are shaved and 1 cm2 sections of skin are cut from
the
dorsal side of sacrificed donors and cleaned in PBS. Two patches of dorsal
skin, 1
cm2 each, are cut from the anesthetized recipients (Nembutal 6 mg/ml, 0.25
ml/mouse) in preparation for the allograft. Two donor allografts per recipient
are
grafted onto the dorsal lesioned patches. Histoacryl (B. Braun Melsungen AG,
Melsungen, Germany) is applied around the graft. Nobecutan (ASTR, Astra Tech,
Glos G15, UK) is sprayed over the grafts.
In the experiment, groups of 6 BALB/c female mice, 8-week old, are grafted
with 1 cm2, full thickness skin grafts from C57BL/6 female mice, 8-week old.
On the
day of grafting, a group of recipient mice is treated either with paraffin oil
or SC
with 100 ~l oleyl alcohol or another immunomodulator according to the
invention.
The day of rejection is scored. The transplanted skin in the mice treated with
the
immunomodulator survives longer in comparison with the untreated control mice.
Example 6. Prevention and treatment of SLE
Systemic lupus erythematosus is an autoimmune disease in which both
autoantibodies and immune complexes are involved. In order to test the
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
immunomodulators of the invention, mice with experimental SLE or
(NZBxNZW)F 1 mice that spontaneously develop autoimmune diseases that closely
resemble SLE, can be used.
In order to induce experimental SLE, BALB/c mice are immunized with the
human or murine anti-DNA monoclonal antibody 16/6Id (20 ~.g/mouse) in CFA in
the hind footpads and boosted 3 weeks later with the same amount of the
immunizing antibody in PBS. The mice are then tested for autoantibody
production
and clinical manifestations characteristic of experimental SLE. In order to
either
prevent induction of experimental SLE or to cure mice afflicted with the
disease,
mice are given oleyl alcohol or another immunomodulator according to the
invention
subcutaneously (100 ~,1 per mouse) before or concomitant with the immunization
and
some weeks after immunization. The number of injections is based on the effect
of
the tested compound on the disease induction and progression. The animals are
regularly weighed and examined for clinical signs of SLE as described, for
example,
in WO 96/30057.
Example 7. Prevention and treatment of autoimmune thyroiditis
Experimental autoimmune thyroiditis (EAT) can be induced in a number of
animals by immunizing with thyroglobulin in CFA. Both humoral antibodies and
TDTH cells directed against the thyrogllobulin develop, resulting in thyroid
inflammation. EAT appears to best mimic Hashimoto's thyroiditis.
EAT is induced as previously described (Rose et al., 1971) by injecting each
mouse subcutaneously with thyroglobulin extract obtained from one thyroid
gland.
The extract is emulsified in IFA (Difco Laboratories, Detroit, Mich.), to
which are
added 7mg/ml lllycobacte~ium tuberculosis, H37Ra strain (Difco Laboratories).
This
injection is repeated one week later. Donors of thyroglobulin extract are mice
of the
C3H/eB strain. 4-5 weeks later, EAT is assayed by removing thyroid glands of
recipient mice, fixing them in 10% formalin solution and then in 70% alcohol,
and
examining microscopic sections stained with hematoxylin and eosin. Microscopic
slides are coded and examined without knowledge of their identity. A diagnosis
of
16
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
EAT is made by observing at least one unequivocal focus of infiltration by
mononuclear cells. Treatment is performed by injecting SC oleyl alcohol or
another
immunomodulator (100 ~,1 per animal) before induction of EAT, concomitant with
or
thereafter (control animals are injected paraffin oil), and the animals are
regularly
weighed and examined for clinical signs of EAT by known conventional methods.
17
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
REFERENCES
Birk et al., 1999. The 60kDa heat shock protein modulates allograft rejection.
Proc.
Nat. Acad. Science USA. 96: 5159-63.
Calder, PC. 1998. Immunoregulatory and anti-inflammatory effects of n-3
polyunsaturated fatty acids. Braz. J. Med. Biol. Res. 31:467-90.
Cohen, IR. 2000, Tending Adam's Ga~deh: Evolving the Cognitive Immure Self.
Academic Press, London, UK.
Cohen, IR. 2000. "Discrimination and Dialogue in the Immune System". Seminars
in
Immunology. 12: 215-219; 269-271; 321-323.
Holoshitz, Y. et al., 1983. "Lines of T lymphocytes mediate or vaccinate
against
autoimmune arthritis", Science 219: 56.
Jaffee, B.D. et al., 1989, "The effect of immunomodulating drugs on adjuvant-
induced arthritis in Lewis rats", Agents Actions. 27 (3-4): 344-6.
Lorentzen J.C. et al., 1995, "Protracted, relapsing and demyelinating
experimental
autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord
and incomplete Freund's adjuvant", J. Neuroimmunology. 63: 193-205.
Pearson, CM. 1964, "Experimental models in rheumatoid disease", Arthritis
Rheum.
7:80.
Pearson, CM. 1956, "Development of arthritis, periarthritis and periostitis in
rats
given adjuvant", Proc. Soc. Exp. Biol. Med. 91:91.
18
CA 02442953 2003-10-03
WO 02/083122 PCT/IL02/00294
Pollock et al., 1989, "Pharmacokinetic analysis of cyclosporine in adjuvant
arthritic
rats", Drug Metab. Dispos. 17 (6): 595-9.
Rodriguez, M.D., Gamez, R., Sanchez, M and H. Garcia. 1998, J. Appl. Toxicol.
18:
313-6.
Rose, N.R., F.J. Twarog and A.J. Crowe. 1971. Murine thryoiditis: importance
of
adjuvant and mouse strain for the induction of thyroid lesions. J. Immuhol.
106:698)
Schwartz, M. and Cohen.IR. 2000, "Autoimmunity can benefit self maintenance".
Immunol Today. 21:265-8.
The Merck Index, 13th Edition, 2001, Merck & Co. Inc., Rahway, N.J., U.S.A.
19
